InvAscent and Morgan Stanley Private Equity Asia have invested INR 10,000 million in Maiva Pharma to enhance its manufacturing capabilities in sterile injectables, underscoring the growing opportunities within India's pharmaceutical sector.

Target Company Overview

Maiva Pharma, headquartered in Bengaluru and established in 1993, is recognized as India's second-largest pure play injectables Contract Development and Manufacturing Organization (CDMO). The company operates a cutting-edge manufacturing facility in Hosur, India, which holds approvals from the US FDA, EU GMP, and ANVISA, ensuring a strong compliance track record. Maiva Pharma offers a robust portfolio of over 75 products, serving more than 40 clients across various global markets, including the US, Canada, Europe, Australia, and Latin America.

The company aims to leverage the newly raised capital of INR 10,000 million to establish an additional manufacturing facility near Hosur. This facility is expected to enhance its capabilities in sterile dosage forms, expanding its offerings to include pre-filled syringes, bags, and specialized injectables for oncology and hormonal treatments.

Industry Overview in India

The pharmaceutical sector in India has emerged as one of the largest in the world, recognized for its extensive product range and manufacturing capabilities. With a strong emphasis on research and development, the Indian pharmaceutical industry has